| Michelle Marie Montalvo, MD, MPH | |
|
1900 10th Ave, Suite 100, Columbus, GA 31901-3600 | |
| (706) 571-1430 | |
| Not Available |
| Full Name | Michelle Marie Montalvo |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 9 Years |
| Location | 1900 10th Ave, Columbus, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518329358 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 008243 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Francis Hospital- Emory Healthcare | Columbus, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southeastern Hospitalist Services Pc | 3476855420 | 276 |
News Archive
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
As the world continues to grapple with the coronavirus pandemic, many scientists, institutions, and pharmaceutical companies are working hard to develop an effective vaccine.
Scare tactics may not be necessary when trying to get patients at risk of heart disease to change their diet or behaviour, a new study has found.
Otsuka Pharmaceutical Co., Ltd., a wholly owned subsidiary of Otsuka Holdings Co., Ltd. based in Japan, announces that on October 20, 2009, pursuant to the private placement disclosed on October 14, 2009, it acquired 3,686,182 newly issued common shares of MethylGene Inc. Following the closing of this private placement, Otsuka Pharmaceutical owns 9.12% of the issued and outstanding common shares of MethylGene.
› Verified 8 days ago
| Entity Name | Southeastern Hospitalist Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003280108 PECOS PAC ID: 3476855420 Enrollment ID: O20160107001140 |
News Archive
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
As the world continues to grapple with the coronavirus pandemic, many scientists, institutions, and pharmaceutical companies are working hard to develop an effective vaccine.
Scare tactics may not be necessary when trying to get patients at risk of heart disease to change their diet or behaviour, a new study has found.
Otsuka Pharmaceutical Co., Ltd., a wholly owned subsidiary of Otsuka Holdings Co., Ltd. based in Japan, announces that on October 20, 2009, pursuant to the private placement disclosed on October 14, 2009, it acquired 3,686,182 newly issued common shares of MethylGene Inc. Following the closing of this private placement, Otsuka Pharmaceutical owns 9.12% of the issued and outstanding common shares of MethylGene.
› Verified 8 days ago
| Entity Name | Muscogee Hospitalist Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639681851 PECOS PAC ID: 8921368564 Enrollment ID: O20180130003094 |
News Archive
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
As the world continues to grapple with the coronavirus pandemic, many scientists, institutions, and pharmaceutical companies are working hard to develop an effective vaccine.
Scare tactics may not be necessary when trying to get patients at risk of heart disease to change their diet or behaviour, a new study has found.
Otsuka Pharmaceutical Co., Ltd., a wholly owned subsidiary of Otsuka Holdings Co., Ltd. based in Japan, announces that on October 20, 2009, pursuant to the private placement disclosed on October 14, 2009, it acquired 3,686,182 newly issued common shares of MethylGene Inc. Following the closing of this private placement, Otsuka Pharmaceutical owns 9.12% of the issued and outstanding common shares of MethylGene.
› Verified 8 days ago
| Entity Name | Benning Hospitalist Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215442173 PECOS PAC ID: 5698038479 Enrollment ID: O20180409000613 |
News Archive
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
As the world continues to grapple with the coronavirus pandemic, many scientists, institutions, and pharmaceutical companies are working hard to develop an effective vaccine.
Scare tactics may not be necessary when trying to get patients at risk of heart disease to change their diet or behaviour, a new study has found.
Otsuka Pharmaceutical Co., Ltd., a wholly owned subsidiary of Otsuka Holdings Co., Ltd. based in Japan, announces that on October 20, 2009, pursuant to the private placement disclosed on October 14, 2009, it acquired 3,686,182 newly issued common shares of MethylGene Inc. Following the closing of this private placement, Otsuka Pharmaceutical owns 9.12% of the issued and outstanding common shares of MethylGene.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michelle Marie Montalvo, MD, MPH 1900 10th Ave, Suite 100, Columbus, GA 31901-3600 Ph: (706) 571-1430 | Michelle Marie Montalvo, MD, MPH 1900 10th Ave, Suite 100, Columbus, GA 31901-3600 Ph: (706) 571-1430 |
News Archive
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
As the world continues to grapple with the coronavirus pandemic, many scientists, institutions, and pharmaceutical companies are working hard to develop an effective vaccine.
Scare tactics may not be necessary when trying to get patients at risk of heart disease to change their diet or behaviour, a new study has found.
Otsuka Pharmaceutical Co., Ltd., a wholly owned subsidiary of Otsuka Holdings Co., Ltd. based in Japan, announces that on October 20, 2009, pursuant to the private placement disclosed on October 14, 2009, it acquired 3,686,182 newly issued common shares of MethylGene Inc. Following the closing of this private placement, Otsuka Pharmaceutical owns 9.12% of the issued and outstanding common shares of MethylGene.
› Verified 8 days ago
Clayton Paul Michael Bellam, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8400 Veterans Pkwy Apt 802, Columbus, GA 31909 Phone: 770-906-0084 | |
Dr. Jeffrey S Jenkins, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 10th Ave, Suite 200, Columbus, GA 31901 Phone: 706-321-3745 Fax: 706-321-3749 | |
Dr. Jefferson C Jones, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 10th Ave, Suite 200, Columbus, GA 31901 Phone: 706-321-3745 Fax: 706-321-3749 | |
Dr. Robert O'neil Snoddy, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 610 19th St, Columbus, GA 31901 Phone: 706-322-7884 Fax: 706-660-2167 | |
Dr. Lisa W. Gantner, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 7901 Veterans Pkwy, Columbus, GA 31909 Phone: 706-321-1223 Fax: 706-321-0819 | |
Shikha Shah, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6200 Bradley Park Dr, Columbus, GA 31904 Phone: 706-591-8080 Fax: 888-905-2571 | |
Anthony Iwelunmor, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 710 Center St, Columbus, GA 31901 Phone: 706-571-1000 |